In October 2013, Bend Research had been acquired by Capsugel becaming part of that firm's Dosage Form Solutions business unit headquartered in Morristown, N.J.. In July 2017, it was announced that Lonza had completed its acquisition of Capsugel, creating a leading integrated solutions provider to the global Pharmaceuticals and Consumer Healthcare industries. Bend Research itself has three facilities in the Bend, Oregon, area providing contract research and development services in the area of commercialization of advanced separations systems based on synthetic membranes and other technologies. Extensively involved in SBIR from the very beginning, their early areas of expertise included advanced gas and liquid separations, immobilized enzymes, controlled-release processes, liquid-absorbent processes, membrane-based solvent extraction processes and thin film optical devices. At that time, Bend's projects and activies were in heavy engineering and industrial related fields: WR Grace, Bethelehm Steel etc were their industrial partners. Bend Research Inc. (BRI) eventually began to specializes in the R&D of novel pharmaceutical-delivery technologies. By 1994, Pfizer had became Bend Researchs sole client under the terms of an agreement that resulted in the development of several novel drug delivery technologies for Pfizer. The relationship helped Bend Research grow from $10 million to more than $40 million in sales during this period. In 2008 the exclusive partnership was ended as part of an overall R&D restructuring by the parties. Over the extensive period of that partnering, Bend Research built an extensive infrastructure, powerful capabilities and know-how in drug development and dru-delivery space.
